PRC Inhibitors
PRC inhibitors, short for Polycomb Repressive Complex inhibitors, are a class of compounds that play a pivotal role in the regulation of gene expression and chromatin structure. These inhibitors are associated with epigenetic modifications, specifically those related to histone methylation, and are involved in maintaining the silencing of certain genes. PRC inhibitors primarily target the Polycomb group proteins, which are essential for controlling gene expression during development and cell differentiation. By understanding the molecular mechanisms of PRC inhibitors, researchers aim to gain insights into the fundamental processes of gene regulation and chromatin remodeling.
Polycomb Repressive Complexes consist of multiple protein subunits, with two main classes known as PRC1 and PRC2. PRC1 is responsible for ubiquitinating histone H2A, leading to chromatin compaction and transcriptional repression. PRC2, on the other hand, catalyzes the methylation of histone H3 at specific lysine residues, further reinforcing gene silencing. PRC inhibitors work by disrupting the interactions between these complexes and their target genes, thereby potentially altering the epigenetic landscape. This disruption can have profound effects on gene expression patterns, impacting various cellular processes.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
WY 14643 | 50892-23-4 | sc-203314 | 50 mg | $136.00 | 7 | |
PPARα agonist that upregulates PPARα-related pathways, potentially reducing PPRC1 activity indirectly. | ||||||
Odanacatib | 603139-19-1 | sc-364675 sc-364675A sc-364675B | 5 mg 25 mg 250 mg | $218.00 $993.00 $1982.00 | 2 | |
PPARα antagonist that may decrease PPARα activity, influencing PPRC1-related transcriptional regulation. | ||||||
GW 9662 | 22978-25-2 | sc-202641 | 5 mg | $70.00 | 30 | |
PPARγ antagonist, can disrupt PPRC1-mediated coactivation of PPARγ, influencing gene expression. | ||||||
T0070907 | 313516-66-4 | sc-203287 | 5 mg | $141.00 | 1 | |
PPARγ antagonist that can affect PPRC1 interaction with PPARγ, altering lipid and glucose metabolism. | ||||||
BADGE | 1675-54-3 | sc-202487 sc-202487A sc-202487B sc-202487C | 25 g 50 g 100 g 500 g | $39.00 $51.00 $64.00 $193.00 | 3 | |
PPARγ antagonist that can affect PPARγ-mediated processes, potentially altering PPRC1 coactivation. | ||||||
Bisphenol A | 80-05-7 | sc-391751 sc-391751A | 100 mg 10 g | $300.00 $490.00 | 5 | |
Environmental compound with potential PPARγ antagonist activity, affecting PPRC1-mediated gene expression. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $41.00 | 9 | |
PPARα agonist that can modulate PPARα activity, possibly impacting PPRC1-related functions. | ||||||
T 0901317 | 293754-55-9 | sc-202824 sc-202824A | 10 mg 50 mg | $89.00 $224.00 | 5 | |
Liver X receptor (LXR) agonist that can influence PPRC1 activity by affecting lipid metabolism. | ||||||
SR 1001 | 1335106-03-0 | sc-507320 | 5 mg | $150.00 | ||
RORα and RORγ inverse agonist that may affect PPRC1 through the regulation of circadian rhythm genes. | ||||||
RKI-1447 | 1342278-01-6 | sc-472590 | 1 mg | $330.00 | ||
LXR antagonist that can influence gene expression profiles regulated by PPRC1. | ||||||